ranopto solution
teva canada limited - ranibizumab - solution - 10mg - ranibizumab 10mg
lucentis solution
novartis pharmaceuticals canada inc - ranibizumab - solution - 10mg - ranibizumab 10mg - eent drugs, miscellaneous
lucentis solution
novartis pharmaceuticals canada inc - ranibizumab - solution - 10mg - ranibizumab 10mg - eent drugs, miscellaneous
byooviz
samsung bioepis nz limited - ranibizumab 10 mg/ml - solution for injection - 10 mg/ml - active: ranibizumab 10 mg/ml excipient: histidine histidine hydrochloride monohydrate polysorbate 20 trehalose dihydrate water for injection - byooviz is indicated for: - the treatment of neovascular (wet) age-related macular degeneration (amd), - the treatment of visual impairment due to diabetic macular oedema (dme), - treatment of proliferative diabetic retinopathy (pdr), - the treatment of visual impairment due to choroidal neovascularisation (cnv), - the treatment of visual impairment due to choroidal neovascularisation (cnv) secondary to pathologic myopia (pm), - the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo).
susvimo solution
hoffmann-la roche limited - ranibizumab - solution - 100mg - ranibizumab 100mg
byooviz ranibizumab 10 mg/ml solution for injection vial
samsung bioepis au pty ltd - ranibizumab, quantity: 2.3 mg - injection, solution - excipient ingredients: water for injections; polysorbate 20; trehalose dihydrate; histidine hydrochloride monohydrate; histidine - byooviz (ranibizumab) is indicated in adults for:,- the treatment of neovascular (wet) age-related macular degeneration (amd),,- the treatment of visual impairment due to diabetic macular oedema (dme),,- treatment of proliferative diabetic retinopathy (pdr),,- the treatment of visual impairment due to choroidal neovascularisation (cnv),,- the treatment of visual impairment due to choroidal neovascularisation (cnv) secondary to pathologic myopia (pm),,- the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (rvo).
raniviz ranibizumab (rbe) 10 mg/ml solution for injection vial
actor pharmaceuticals pty ltd - ranibizumab, quantity: 10 mg/ml - injection, solution - excipient ingredients: water for injections; histidine hydrochloride monohydrate; trehalose dihydrate; polysorbate 20; histidine - raniviz (ranibizumab) is indicated in adults for:,? the treatment of neovascular (wet) age-related macular degeneration (amd),,? the treatment of visual impairment due to diabetic macular oedema (dme),,? treatment of proliferative diabetic retinopathy (pdr),,? the treatment of visual impairment due to choroidal neovascularisation,,? the treatment of visual impairment due to choroidal neovascularisation (cnv) secondary to pathologic myopia (pm),,? the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (rvo).,not recommended for use in preterm infants.
accentrix 10mgml solution for injection
novartis corporation (malaysia) sdn. bhd. - ranibizumab -
lucentis solution for injection in pre-filled syringe 1.65mg0.165ml
novartis (singapore) pte ltd - ranibizumab - injection, solution - ranibizumab 1.65mg/0.165ml
lucentis 10 mg/ml
شركة مستودع الأدوية الأردني - the jordan drugstore co - ranibizumab 10 mg/ml - 10 mg/ml